Insulet Co. (NASDAQ:PODD) Shares Acquired by Victory Capital Management Inc.

Victory Capital Management Inc. boosted its stake in Insulet Co. (NASDAQ:PODD) by 5.1% during the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 35,706 shares of the medical instruments supplier’s stock after buying an additional 1,724 shares during the quarter. Victory Capital Management Inc. owned approximately 0.05% of Insulet worth $8,311,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also modified their holdings of PODD. Blue Trust Inc. grew its position in Insulet by 84.1% in the 3rd quarter. Blue Trust Inc. now owns 127 shares of the medical instruments supplier’s stock valued at $30,000 after buying an additional 58 shares in the last quarter. Venturi Wealth Management LLC raised its holdings in shares of Insulet by 633.3% during the 3rd quarter. Venturi Wealth Management LLC now owns 154 shares of the medical instruments supplier’s stock valued at $36,000 after purchasing an additional 133 shares in the last quarter. International Assets Investment Management LLC bought a new stake in shares of Insulet during the 2nd quarter worth about $32,000. UMB Bank n.a. grew its holdings in Insulet by 81.0% during the second quarter. UMB Bank n.a. now owns 181 shares of the medical instruments supplier’s stock valued at $37,000 after purchasing an additional 81 shares during the last quarter. Finally, CVA Family Office LLC raised its holdings in Insulet by 138.1% in the 2nd quarter. CVA Family Office LLC now owns 250 shares of the medical instruments supplier’s stock worth $50,000 after acquiring an additional 145 shares during the period.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on the company. Barclays lifted their price objective on Insulet from $220.00 to $234.00 and gave the company an “equal weight” rating in a report on Monday, November 11th. Raymond James raised their price objective on shares of Insulet from $213.00 to $260.00 and gave the stock an “outperform” rating in a report on Monday, October 14th. Sanford C. Bernstein started coverage on Insulet in a report on Wednesday, November 6th. They set an “outperform” rating and a $300.00 target price on the stock. Citigroup raised their target price on shares of Insulet from $250.00 to $275.00 and gave the company a “buy” rating in a research note on Tuesday, October 1st. Finally, UBS Group upped their target price on shares of Insulet from $211.00 to $223.00 and gave the company a “neutral” rating in a report on Friday, August 9th. Three research analysts have rated the stock with a hold rating and twelve have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $253.27.

Insulet Stock Down 1.3 %

Shares of NASDAQ:PODD opened at $262.99 on Friday. The stock’s 50-day moving average price is $240.74 and its 200-day moving average price is $209.99. The company has a current ratio of 3.68, a quick ratio of 2.80 and a debt-to-equity ratio of 1.21. Insulet Co. has a 12-month low of $160.19 and a 12-month high of $279.40. The stock has a market capitalization of $18.45 billion, a P/E ratio of 45.03, a price-to-earnings-growth ratio of 4.01 and a beta of 1.22.

Insulet Profile

Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company's Omnipod platform includes the Omnipod 5 Automated Insulin Delivery System (Omnipod 5) which includes a proprietary AID algorithm embedded in the Pod that integrates with a third-party continuous glucose monitor to obtain glucose values through wireless bluetooth communication; Omnipod DASH that features a bluetooth enabled Pod that is controlled by a smartphone-like Personal Diabetes Manager with a color touch screen user interface; and Omnipod GO, a standalone, wearable, insulin delivery system that provides a fixed rate of continuous rapid-acting insulin for 72 hours.